Shares of Halozyme Therapeutics Inc. (NASDAQ:HALO) rose 1.9% during mid-day trading on Friday . The company traded as high as $8.91 and last traded at $8.80, with a volume of 621,528 shares trading hands. The stock had previously closed at $8.64.

HALO has been the topic of a number of research reports. Jefferies Group restated a “sell” rating and set a $6.75 price objective on shares of Halozyme Therapeutics in a research report on Tuesday, May 10th. Piper Jaffray Cos. restated an “overweight” rating and set a $15.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, June 23rd. Wells Fargo & Co. restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, June 8th. Finally, Canaccord Genuity restated a “buy” rating and set a $11.00 price objective on shares of Halozyme Therapeutics in a research report on Monday, June 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $15.68.

The firm’s 50 day moving average price is $8.98 and its 200 day moving average price is $9.76. The company’s market cap is $1.13 billion.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.04. During the same period last year, the company posted ($0.12) earnings per share. The company had revenue of $42.50 million for the quarter, compared to analyst estimates of $29.65 million. The business’s revenue for the quarter was up 127.3% on a year-over-year basis. On average, equities analysts anticipate that Halozyme Therapeutics Inc. will post ($1.03) EPS for the current fiscal year.

A number of hedge funds and institutional investors recently modified their holdings of HALO. Nationwide Fund Advisors boosted its position in shares of Halozyme Therapeutics by 2.3% in the fourth quarter. Nationwide Fund Advisors now owns 69,817 shares of the biopharmaceutical company’s stock valued at $1,210,000 after buying an additional 1,563 shares during the period. ProShare Advisors LLC boosted its position in shares of Halozyme Therapeutics by 9.8% in the fourth quarter. ProShare Advisors LLC now owns 122,509 shares of the biopharmaceutical company’s stock valued at $2,123,000 after buying an additional 10,937 shares during the period. California State Teachers Retirement System boosted its position in shares of Halozyme Therapeutics by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 196,510 shares of the biopharmaceutical company’s stock valued at $3,406,000 after buying an additional 3,096 shares during the period. Tekla Capital Management LLC bought a new position in shares of Halozyme Therapeutics during the fourth quarter valued at approximately $3,466,000. Finally, California Public Employees Retirement System boosted its position in shares of Halozyme Therapeutics by 10.2% in the fourth quarter. California Public Employees Retirement System now owns 255,600 shares of the biopharmaceutical company’s stock valued at $4,430,000 after buying an additional 23,600 shares during the period.

Halozyme Therapeutics, Inc is a biotechnology company, which is focused on developing and commercializing oncology therapies that target the tumor microenvironment. The Company’s development pipeline consists primarily of clinical-stage product candidates in oncology and diabetes. The product candidates in its pipeline are based on rHuPH20, a human recombinant hyaluronidase enzyme.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.